Get the Stockscreener App
24.05
0.37%
-0.0903
Flexion Therapeutics, Inc. stock is traded at $24.05, with a volume of 1,458.
It is down -0.37% in the last 24 hours and down -2.15% over the past month.
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee. The company also develops FX101 and FX201, which is a pre-clinical stage programs for the treatment OA of large joints. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.
See More
Previous Close:
$24.15
Open:
$24.05
24h Volume:
1,458
Relative Volume:
0.04
Market Cap:
$N/A
Revenue:
$102.74M
Net Income/Loss:
$-95.05M
P/E Ratio:
-12.80
EPS:
-1.88
Net Cash Flow:
$-19.23M
1W Performance:
-0.45%
1M Performance:
-2.15%
6M Performance:
-6.35%
1Y Performance:
-5.89%
1-Day Range:
$24.04
$24.09
1-Week Range:
$24.11
$24.25
52-Week Range:
$23.87
$26.09
Flexion Therapeutics, Inc. Stock (FLXN) Company Profile
Name
Flexion Therapeutics, Inc.
Sector
Industry
Phone
781-305-7777
Address
10 Mall Road, Suite 301, Burlington
Compare FLXN vs VOO, IVV, SPY, VTI, QQQ
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FLXN
Flexion Therapeutics, Inc.
|
24.05 | 0 | 102.74M | -95.05M | -19.23M | -1.88 |
VOO
Vanguard S P 500 Etf
|
710.46 | 1.05T | 0 | 0 | 0 | 0.00 |
IVV
Ishares Core S P 500 Etf
|
776.35 | 890.86B | 0 | 0 | 0 | 0.00 |
SPY
Spdr S P 500 Etf Trust
|
772.91 | 816.30B | 0 | 0 | 0 | 0.00 |
VTI
Vanguard Total Stock Market Etf
|
378.64 | 697.37B | 0 | 0 | 0 | 0.00 |
QQQ
Invesco Qqq Trust Series 1
|
736.03 | 492.26B | 0 | 0 | 0 | 0.00 |
Flexion Therapeutics, Inc. Stock (FLXN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Aug-20-20 | Initiated | Goldman | Neutral |
| Jul-31-20 | Initiated | Oppenheimer | Outperform |
| Jul-29-20 | Initiated | Credit Suisse | Outperform |
| Jun-25-20 | Initiated | H.C. Wainwright | Buy |
| May-27-20 | Initiated | Guggenheim | Buy |
| Dec-27-19 | Reiterated | The Benchmark Company | Buy |
| Dec-05-19 | Initiated | Craig Hallum | Buy |
| Nov-25-19 | Initiated | BTIG Research | Buy |
| May-09-19 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-04-19 | Reiterated | Needham | Buy |
| Jan-04-19 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-28-18 | Initiated | The Benchmark Company | Buy |
| Oct-09-17 | Reiterated | Needham | Buy |
| Aug-24-17 | Initiated | Northland Capital | Outperform |
| Dec-22-16 | Initiated | Raymond James | Strong Buy |
| Sep-06-16 | Resumed | Lake Street | Buy |
| Jul-21-16 | Initiated | Lake Street | Buy |
| May-03-16 | Resumed | Wells Fargo | Outperform |
| Nov-04-15 | Initiated | Cantor Fitzgerald | Buy |
| Sep-09-15 | Reiterated | Needham | Buy |
View All
Flexion Therapeutics, Inc. Stock (FLXN) Latest News
Top ETFs: Live Prices, Returns & Trends - TradingKey
First Trust Advisors L.P. Announces Distributions for Exchange-Traded Funds - Business Wire
FLXR And BINC: Both Diversified, Higher-Quality Bond ETFs, Both Buys - Seeking Alpha
First Trust Announces Adjournment of Special Shareholder Meeting for First Trust Active Global Quality Income ETF - Yahoo Finance
First Trust Announces Adjournment of Special Shareholder Meeting for First Trust Active Global Quality Income ETF - Yahoo Finance
FLXN | Horizon Flexible Income ETF Insider Trading - Quiver Quantitative
Emerging Sub-Segments Transforming the Viscosupplementation Market Landscape - openPR.com
Kolon’s cell-based gene therapy fails ph.3 osteoarthritis test - Fierce Biotech
Precision Trading with Blackrock Flexible Income Etf (BINC) Risk Zones - Stock Traders Daily
Joint Pain Injections Market Report Examines Industry Trends, Growth Drivers And Future Outlook - openPR.com
Osteoarthritis Market Expected to Showcase Moderate Growth at a CAGR of 3% During the Forecast Period (2026–2036) Driven by Emerging Therapies and Rising Disease Burden | DelveInsight - Business Upturn
Osteoarthritis Therapeutics Market Size & Share | Forecast Report 2035 - Research Nester
Tempest Therapeutics appoints two directors to board By Investing.com - Investing.com Australia
Tempest Therapeutics appoints two directors to board - Investing.com UK
Tempest Therapeutics appoints two directors to board By Investing.com - Investing.com India
Tempest Therapeutics (NASDAQ: TPST) CFO to depart while two independent directors join board - Stock Titan
Tempest Therapeutics appoints two directors to board - Investing.com
Tempest Therapeutics appoints two directors to board By Investing.com - Investing.com Canada
Tempest Therapeutics appoints two directors to board By Investing.com - Investing.com UK
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors - The Manila Times
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors - GlobeNewswire
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors - Yahoo Finance Singapore
The Best Bond Funds in 2026 - Morningstar
Osteoarthritis Market Gains Momentum with Expanding Pipeline and Investment Potential by 2036 – DelveInsight | Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharma - Barchart.com
FLXN Stock Price, Quote & Chart | HORIZON FLEXIBLE INCOME ETF (NYSEARCA:FLXN) - ChartMill
Top Players and Competitive Dynamics in the Osteoarthritis Therapeutics Market - openPR.com
BINC Can Help Stabilize The Portfolio’s Future Returns (NYSEARCA:BINC) - Seeking Alpha
Knee Osteoarthritis Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com
Knee Osteoarthritis Clinical Trial Pipeline Appears Robust - openPR.com
Versant Side Fund III L P Net WorthInsider Trades and Bio as of Apr 23, 2026 - Benzinga
Analysis of Key Market Segments Driving the Joint Pain Injections Market - openPR.com
Flexion Therapeutics, Inc.Common Stock (NY: FLXN - The Chronicle-Journal
Akin Advises Pharmakon in $100 Million Debt Financing for Paratek Pharmaceuticals and Radius Health Combination - akingump.com
Paratek Pharmaceuticals to Combine with Radius Health, Expanding Its Multi-Product Specialty Commercial Platform - Sixth Street
Activist hedge fund pushes Pacira BioSciences to sell itself - The Business Journals
Intra-Articular Injections Market Companies, Size & Trends 2026-2035 - Precedence Research
BINC: Actively Managed Multi-Sector Income, Built For Carry (NYSEARCA:BINC) - Seeking Alpha
Record January ETF Flows Highlight Rotation Away From Concentration - ETF Database
PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates - Finviz
Meredith Marlin Appointed as SVP, Total Rewards at Regeneron - hrtoday.in
The Standing Forward Flexion Test in Manual Therapy: A Critical Review and a Functional Reinterpretation - Cureus
Osteoarthritis Therapeutics Market Size to Hit USD 26.31 billion by 2035 - Precedence Research
Biotech Companies Hire New Legal Leadership - BioXconomy
PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer - Business Wire
Horizon Announces Acquisition of Anfield Capital Management - Business Wire
What’s a Safe Retirement Withdrawal Rate for 2026? - Morningstar
Your retirement income journey: Why your withdrawal rate will change over time - Moneyweb
Horizon NASDAQ-100 Defined Risk ETF (QGRD) Stock Price, News, Quote & History - Yahoo! Finance Canada
Unlock a Worry-Free Retirement With ETFs - Investopedia
Horizon Flexible Income ETF (FLXN) Stock Price, News & Analysis - Stock Titan
Flexion Therapeutics, Inc. Stock (FLXN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.12%
Cap:
|
Volume (24h):